Shots:

• Molecular Partners collaborated with the University of Bern to evaluate the effect and MoA of its DARPin candidate TCE in AML by using in vitro and in vivo models along with patient samples
• The collaboration will utilize Molecular Partners’ DARPin technology and the University of Bern group’s expertise in AML to assess the novel therapeutic option & advance AML methodologies and patient samples
• MP0533 is a DARPin & is designed to engage CD3 on T cells and target three tumor-associated antigens to achieve high specificity and broad cancer cell coverage. Additionally, Molecular Partners develops multiple products which are designed to activate the immune system to fight cancer

/ article | Ref: Globe Newswire | Image: Swiss Biotech Association